Nature·2 min read·medium
Cancer-fighting antibodies with a one-two punch take aim at tumours
L
Ledford, Heidi
✦AI Summary
Bispecific antibodies, which target two proteins simultaneously, are seeing a surge in clinical adoption and commercial success. With over 20 approvals globally, these advanced cancer-fighting drugs generated $18 billion in sales in 2025.
Heidi Ledford reports for Nature from Seattle, Washington.
sciencehealthbusiness
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in